Condition: Solid Tumor, Adult · Carcinoma, Ovarian Epithelial · Fallopian Tube Neoplasms · Sponsor: Bio-Path Holdings, Inc.
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
This description comes directly from the study's public registry record.
Brian Forbes · 832-742-1365 · bforbes@biopathholdings.com
Michael Hickey · 832-742-1361 · mhickey@biopathholdings.com
Always discuss trial participation with your own doctor first.
| Holy Cross Hospital | Silver Spring, Maryland, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| The University of Texas M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04196257